Effects of Incremental Dietary Levels of Ground Flaxseed on Milk Production, Ruminal Metabolism, and Enteric Methane Emissions in Organic Dairy Cows

Ground Flaxseed (Linum uitatissimum) is a lipid supplement that is commonly fed to dairy cows. It is believed that supplemental lipid can change the Fatty Acid (FA) composition in the milk, and decrease methane production. Twenty lactating organic Jersey cows, housed at the UNH Organic Dairy Research Farm (ODRF), were randomly assigned to five replicated 4 × 4 Latin squares to investigate the effects of increasing dietary levels of ground flaxseed (0, 5, 10, or 15% of the diet dry matter) on animal fperformance (e.g., dry matter intake, milk production, milk composition), ruminal metabolism, and enteric methane emissions. Each period lasted 21 days with 14 days for diet adaptation and seven days for data and samples collection. Cows were fed twice daily (a.m. and p.m.) a total mixed ration containing 65% grass-legume baleage, and one of the following supplemental mixturess: 0% ground flaxseed, 27% corn meal, and 8% soybean meal 5% ground flaxeed, 24% corn meal, and 6% soybean meal 10% ground flaxseed, 21% corn meal, and 4% soybean meal 15% ground flaxseed, 17.5 corn meal, and 2.5% soybean meal. Feeding incremental dietary levels of ground flaxseed resulted in linear decreases of dry matter intake, yields of milk and milk components, ruminal molar proportion of acetate and butyrate, and enteric methane emissions. However, the molar proportion of propionate increased linearly with feeding incremental dietary levels of ground flaxseed. Further research is needed to investigate the long-term effects of ground flaxseed on milk yield and animal health

Highlights From the Annual Meeting of the American Epilepsy Society 2022

With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 1.2 × 10-6 , BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6-3.4, P = 1.6 × 10-5 , BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 2.3 × 10-5 , BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.Includes NIHR and CRUK

Locust Grove Nature Center

Final project for LARC642 Graduate Landscape Architecture Studio III (Fall 2017). University of Maryland, College Park.Today Locust Grove Nature Center is housed in a small, aging retrofit facility adapted from a toboggan run that opened its doors in 1972, operating for a few short years before shuttering in 1977. The current demand for year-round programming and multi-functional event space far exceeds Locust Grove’s capacity. The location of the nature center uniquely positions Locust Grove to serve as an in-demand local resource that draws a diverse array of visitors from across Montgomery County. One of its primary advantages is its proximity to Cabin John Creek, and thus also its position within the greater Cabin John Regional Park. The ecological amenities of Cabin John include unique natural landforms and wildlife habitats associated with Maryland’s Piedmont region. Locust Grove’s trail system and grounds present the rich story of natural heritage located well within the urbanized boundaries of the county. Another significant benefit of Locust Grove’s location is its position along Democracy Boulevard near the I-270 interchange with the Capital Beltway. This immediate proximity to the Beltway, the backbone of D.C. metro area’s circulation, provides convenient access from most areas of Montgomery County and the greater D.C. metro region. Locust Grove has excellent visibility from this major arterial road which is unique among comparable nature centers in this region. In addition, its topography is naturally suited for supporting a large structure. Locust Grove has ample acreage of high quality, gently sloped land available to suit a major new facility that could meet the growing demand for this type of facility. This report reviews a series of high profile nature centers recently built across the United States including two prominent facilities located in Maryland: Robinson Nature Center in Howard County and Irvine Nature Center in Baltimore County. It also examines the natural features of Cabin John Park to identify opportunities and constraints related to nature center design. Additionally, one chapter is devoted to reviewing important design standards including site accessibility, vehicular circulation, stormwater management, and habitat restoration. Finally, three alternative conceptual designs are presented as an exercise in generating idea for the design of a new nature center for Locust Grove.Montgomery Count

Cuadernos de pedagogía

El artículo forma parte de un dossier titulado: El desafío de la diversidad : un estímulo para el desarrollo profesionalEl proyecto que ha dado origen al artículo, Responding to Diversity by Engaging with Students’ Voices: A Strategy for Teacher Development, está financiado con el apoyo de la Comisión Europea en el marco del Life Learning Programme. European Union Comenius Multilateral Project (RD-SVTD, 2011-2014)En publicación aparece Ignacio ZapateroSe describe cómo se lleva a la práctica el proyecto multilateral Comenius del Life Learning Programme, de la Unión Europea en los ocho centros de Secundaria participantes. Cuatro institutos ingleses (dos de Manchester y dos de Hull), dos españoles (en Madrid) y dos portugueses (en Lisboa) comparten propósitos semejantes: conseguir prácticas de aula más inclusivas, fomentar un aprendizaje significativo y entender la diversidad del alumnado como una oportunidad de la que aprender.Madrid (Comunidad Autónoma). Subdirección General de Formación del Profesorado. CRIF Las Acacias; Calle General Ricardos 179; 28025 Madrid; Tel. +34915250893; Fax +34914660991; [email protected]

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

Abstract Background: We examined associations between suicidality and genotypes that predict plasma efavirenz exposure among AIDS Clinical Trials Group study participants in the United States. Methods: Four clinical trials randomly assigned treatment-naive participants to efavirenz-containing regimens; suicidality was defined as reported suicidal ideation or attempted or completed suicide. Genotypes that predict plasma efavirenz exposure were defined by CYP2B6 and CYP2A6 polymorphisms. Associations were evaluated with weighted Cox proportional hazards models stratified by race/ethnicity. Additional analyses adjusted for genetic ancestry and selected covariates. Results: Among 1833 participants, suicidality was documented in 41 in exposed analyses, and 34 in on-treatment analyses. In unadjusted analyses based on 12 genotype levels, suicidality increased per level in exposed (hazard ratio, 1.11; 95% confidence interval, .96–1.27) and on-treatment 1.16; 1.01–1.34) analyses. In the on-treatment analysis, the association was strongest among white but nearly null among black participants. Considering 3 metabolizer levels (extensive, intermediate and slow), slow metabolizers were at increased risk. Results were similar after baseline covariate-adjustment for genetic ancestry, sex, age, weight, injection drug use history, and psychiatric history or recent psychoactive medication. Conclusions: Genotypes that predict higher plasma efavirenz exposure were associated with increased risk of suicidality. Strength of association varied by race/ethnicity